title: The efficacy of steroids in idiopathic facial nerve paralysis: an open, randomized, prospective controlled study.
abstract: OBJECTIVE
  Although corticosteroid therapy is widely used in idiopathic facial nerve paralysis, its efficacy has not been clearly demonstrated. This study was designed to evaluate the role of steroids in idiopathic facial nerve paralysis.
  
  
  METHODS
  The study included 56 patients (29 males, 27 females; mean age, in men 44.1, in women 40.3 years) with a diagnosis of idiopathic facial nerve paralysis. Within the first three days after the onset of symptoms, the patients were randomly assigned to two groups to receive either steroids or other medications for the prevention of ocular complications or to provide pain relief. The severity of facial paralysis was evaluated using the House-Brackmann classification before and after three and six weeks of the treatment. Regression to stage 1 or 2 disease was regarded as a successful response.
  
  
  RESULTS
  Although the initial response to steroid therapy seemed to be better, the results at the end of three and six weeks of the treatment were not statistically different from those of patients receiving other supportive treatments (p>0.05).
  
  
  CONCLUSIONS
  Further studies with large patient series are needed to clarify the use of steroids in the treatment of idiopathic facial nerve paralysis.
authors.affiliation: Department of Neurology, Dr. Lütfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey.
authors.forename: Ulkü
authors.initials: U
authors.lastname: Türk-Börü
authors.forename: Abdulkadir
authors.initials: A
authors.lastname: Koçer
authors.forename: Cevdet
authors.initials: C
authors.lastname: Bilge
mesh_terms: D000284:Administration, Oral; D000328:Adult; D020330:Bell Palsy / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D008775:Methylprednisolone